During a recent appearance on FOX Business, Dr. Mehmet Oz announced that oral weight-loss pills are expected to replace GLP-1 injections by March 2026. This transition is part of broader efforts by the Trump administration to enhance health outcomes for Americans. Dr. Oz highlighted that pharmaceutical companies are rapidly advancing their technologies, leading to the development of these oral medications, which are anticipated to be priced at approximately $150 per month.
Dr. Oz emphasized the importance of traditional methods for weight management, such as diet and exercise, but acknowledged that for some individuals, medications like GLP-1 drugs serve as a necessary support. He posited that the implementation of these oral medications could contribute to significant weight loss across the population, with projections indicating a reduction of 135 million pounds over the next year. Such weight loss may subsequently reduce the incidence of health issues, including heart disease.
The discussion included details on pricing strategies from pharmaceutical companies. Novo Nordisk announced plans to lower prices for their injectable drugs, including Wegovy and Ozempic, to enhance accessibility under Medicare and Medicaid programs. Meanwhile, Lilly plans to offer Zepbound and Orforglipron at reduced rates, with self-pay prices significantly lower than current offerings.
These developments in weight-loss medications reflect a growing trend in the healthcare sector, where medications initially designed for diabetes management are being repurposed for obesity treatment. As the landscape of obesity treatment evolves, the anticipated shift from injections to oral medications may provide new options for patients seeking assistance in managing their weight.